Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coşkun, Kyle W. Sloop, Corina Loghin, et al.
Molecular Metabolism (2018) Vol. 18, pp. 3-14
Open Access | Times Cited: 575

Showing 1-25 of 575 citing articles:

Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 3, pp. 205-216
Open Access | Times Cited: 1714
Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1306
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie J. Davies, Julio Rosenstock, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 6, pp. 503-515
Open Access | Times Cited: 1117
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 688
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock, Carol Wysham, Juan P. Frías, et al.
The Lancet (2021) Vol. 398, Iss. 10295, pp. 143-155
Closed Access | Times Cited: 664
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism
Fiona M. Gribble, Frank Reimann
Nature Reviews Endocrinology (2019) Vol. 15, Iss. 4, pp. 226-237
Closed Access | Times Cited: 499
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato, Steven E. Kahn, Imre Pávó, et al.
The Lancet (2021) Vol. 398, Iss. 10313, pp. 1811-1824
Closed Access | Times Cited: 434
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, et al.
The Lancet (2021) Vol. 398, Iss. 10300, pp. 583-598
Closed Access | Times Cited: 421
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Angelica Artasensi, Alessandro Pedretti, Giulio Vistoli, et al.
Molecules (2020) Vol. 25, Iss. 8, pp. 1987-1987
Open Access | Times Cited: 376
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff, et al.
The Lancet (2023) Vol. 402, Iss. 10402, pp. 613-626
Open Access | Times Cited: 323
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 393-406
Closed Access | Times Cited: 317
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard, Jonathan D. Douros, M Gabe, et al.
JCI Insight (2020) Vol. 5, Iss. 17
Open Access | Times Cited: 301
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms, Matthew P. Coghlan, Kyle W. Sloop
Trends in Endocrinology and Metabolism (2020) Vol. 31, Iss. 6, pp. 410-421
Open Access | Times Cited: 277
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman, Arun J. Sanyal, Rohit Loomba, et al.
Diabetes Care (2020) Vol. 43, Iss. 6, pp. 1352-1355
Open Access | Times Cited: 267
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Louis J. Aronne, Naveed Sattar, Deborah B. Horn, et al.
JAMA (2023) Vol. 331, Iss. 1, pp. 38-38
Open Access | Times Cited: 261
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens, Emma K. Biggs, Tamana Darwish, et al.
Cell Metabolism (2019) Vol. 30, Iss. 5, pp. 987-996.e6
Open Access | Times Cited: 243
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Naveed Sattar, Darren K. McGuire, Imre Pávó, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 591-598
Open Access | Times Cited: 239
Therapeutic pipeline in nonalcoholic steatohepatitis
Raj Vuppalanchi, Mazen Noureddin, Naim Alkhouri, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 6, pp. 373-392
Closed Access | Times Cited: 233
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio, Daniel J. Drucker
Molecular Metabolism (2020) Vol. 46, pp. 101090-101090
Open Access | Times Cited: 220
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Thinzar Min, Stephen C. Bain
Diabetes Therapy (2020) Vol. 12, Iss. 1, pp. 143-157
Open Access | Times Cited: 207
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Melissa K. Thomas, Amir Nikooienejad, Ross Bray, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 106, Iss. 2, pp. 388-396
Open Access | Times Cited: 204
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Michael A. Nauck, Jakob Wefers, Juris J. Meier
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 525-544
Closed Access | Times Cited: 203
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang, Tenagne D. Challa, Robert Augustin, et al.
Cell Metabolism (2021) Vol. 33, Iss. 4, pp. 833-844.e5
Open Access | Times Cited: 192
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Rohit Loomba, Mark L. Hartman, Eric Lawitz, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 4, pp. 299-310
Closed Access | Times Cited: 188
Page 1 - Next Page

Scroll to top